Instructions on the injection dosage and frequency of rubicatin/rubitin

Lurbinectedin is an alkylating agent primarily used to treat metastatic small cell lung cancer (SCLC). It achieves anti-tumor effects by targeting and inhibiting the DNA synthesis of cancer cells and preventing the proliferation of cancer cells. For patients with SCLC, the recommended method of use of rubitidine is intravenous injection, and its dosage and frequency of administration are determined based on the patient's body surface area (BSA).

According to the current treatment regimen, the standard dose of rubitidine is 3.2 mg/m² of body surface area every 21 days. That is, the patient needs to receive one injection per treatment cycle, and the dose is determined based on the patient's body surface area. The drug is administered via intravenous injection, generally in a medical institution, and patients cannot inject themselves. A 21-day interval is required between each course of treatment to ensure that the medication works optimally in the body and to reduce the risk of side effects.

The common drug specification of rubitidine is 4mg/bottle, and patients usually need to choose the appropriate dose based on the calculation of their own body surface area. During the treatment process, doctors will regularly evaluate the efficacy and adjust the dosage based on the patient's response and drug concentration in the body to ensure the maximum effect of the treatment.

The treatment plan for rubitidine is usually long-term, so patients need to undergo regular physical examinations and biochemical examinations to monitor the impact of the drug on liver and kidney function. During clinical treatment, doctors will closely track the patient's side effects and adjust the treatment frequency or dose as needed to ensure the patient's therapeutic effect and safety.

Generally speaking, the dosage regimen of rubitidine is standardized to a certain extent, but it still needs to be individually adjusted according to the specific conditions of each patient to ensure the best therapeutic effect and minimal side effects.

Reference materials:https://www.zepzelca.com/